MarketCap
Facebook
X
TelegramQuartalsbericht 2026-Q1
hinzugefügt 08.05.2026
Assertio Holdings Langfristige Verbindlichkeiten 2011-2026 | ASRT
Langfristige Verbindlichkeiten Jährlich Assertio Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 115 M | 285 M | 466 M | 559 M | 747 M | 829 M | 289 M | 214 M | 21 M | 18.6 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 829 M | 18.6 M | 354 M |
Langfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 5.66 | 0.98 % | $ 84.1 M | USA |
 |
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.12 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
10.7 M | $ 2.72 | 1.49 % | $ 1.04 B | Canada |
 |
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
19.8 M | $ 38.34 | 1.86 % | $ 1.41 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
134 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
105 M | $ 2.42 | 3.21 % | $ 307 M | USA |
 |
Pacira BioSciences
PCRX
|
368 M | $ 23.0 | 0.04 % | $ 1.06 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 1.12 | 2.75 % | $ 1.39 M | USA |
 |
Aurora Cannabis
ACB
|
681 M | $ 3.17 | 4.11 % | $ 174 M | Canada |
 |
Solid Biosciences
SLDB
|
19.1 M | $ 7.3 | 2.17 % | $ 639 M | USA |
 |
Jupiter Wellness
JUPW
|
114 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.07 | 0.47 % | $ 102 M | Canada |
 |
Tilray
TLRY
|
570 M | $ 5.14 | 3.21 % | $ 3.18 B | Canada |
 |
cbdMD
YCBD
|
2.49 M | $ 0.71 | 3.49 % | $ 2.86 M | USA |
 |
Evolus
EOLS
|
102 M | $ 6.68 | -0.74 % | $ 431 M | USA |
 |
Sundial Growers
SNDL
|
1.03 M | $ 1.46 | 2.46 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.02 B | $ 8.41 | 1.08 % | $ 450 M | USA |
 |
Veru
VERU
|
6.71 M | $ 3.05 | 1.61 % | $ 44.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
3.28 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
26.5 B | $ 5.13 | 1.38 % | $ 1.9 B | Canada |
 |
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
2.66 M | $ 6.64 | -0.15 % | $ 262 M | USA |
 |
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
53.4 M | $ 4.25 | 0.47 % | $ 212 M | USA |
 |
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
13.8 B | $ 16.43 | -0.27 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
275 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
11.6 M | $ 0.64 | 2.32 % | $ 23 M | USA |
 |
Tricida
TCDA
|
13.2 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
1.71 M | $ 0.77 | 7.74 % | $ 3.3 M |  China |
 |
TherapeuticsMD
TXMD
|
246 M | $ 2.29 | 4.09 % | $ 26.5 M | USA |